Rituximab vs Tofacitinib

## Rituximab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Rituximab** and **Tofacitinib**.

## Mechanism of Action

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Rituximab — 22 days; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Rituximab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Rituximab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Rituximab — Antibody; Tofacitinib — Small molecule.